<DOC>
	<DOCNO>NCT02719184</DOCNO>
	<brief_summary>The study include 125 healthy subject ( ex-smoker without airflow limitation ) , 125 COPD GOLD ( global initiative chronic obstructive lung disease ) I , 125 COPD GOLD II , 125 COPD GOLD III 40 ( minimum 20 ) patient COPD A1AT ( Alpha1-Antitrypsin ) deficiency ( ZZ genotype ) . Soluble image biomarkers investigate address different aspect disease pathway postulate relevant COPD progression .</brief_summary>
	<brief_title>Longitudinal Follow Assess Biomarkers Predictive Emphysema Progression Patients With COPD ( Chronic Obstructive Pulmonary Disease )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Inclusion criterion : General Inclusion Criteria Male female healthy subject COPD ( GOLD I III ) outpatient without A1AT deficiency . Exsmoker smoke history &gt; =20 pack year Signed informed consent consistent ICHGCP ( International Conference Harmonisation Good Clinical Practice ) guideline prior participation study , include medical shortterm restriction Age &gt; = 40 &lt; =60 year Body mass index ( BMI ) &gt; = 18 &lt; = 30 kg/m2 Ability perform study relate procedure include technically acceptable pulmonary function test , body plethysmography , DLCO ( Diffusing Capacity lungs Carbon Monoxide ) , sputum induction , HRCT ( High Resolution Computed Tomography ) MRI ( applicable ) Inclusion Criteria Specific Patients COPD Patients must current diagnosis COPD make physician least 3 month prior Visit 1 mMRC ( Modified Medical Research Council Dyspnea Scale ) score 1 . The diagnosis COPD must accordance GOLD Guidelines must document follow criterion : Known relatively stable airway obstruction postbronchodilator FEV1 ( Forced Expiratory Volume first second ) /FVC ( Forced Vital Capacity ) &lt; low limit normal ( GLI 2012 ) The current COPD must mild , moderate severe base lung function symptom clinical situation must stabilize least 6 week prior Visit 1 . The following definition adapt GOLD Guidelines apply : 1. mild : postbronchodilator FEV1 predict &gt; =80 % ( GLI 2012 ) Visit 1 2. moderate : 50 % &lt; = postbronchodilator FEV1 predict &lt; 80 % ( GLI 2012 ) without chronic respiratory failure Visit 1 3. severe : 30 % &lt; = postbronchodilator FEV1 predict &lt; 50 % ( GLI 2012 ) without chronic respiratory failure Visit 1 Patients must stable therapy least 6 month Inclusion Criteria Specific Patients COPD A1AT Deficiency Documented diagnosis A1AT deficiency ZZ genotype Inclusion Criteria Specific Healthy Subjects Normal lung function value Visit 1 documented postbronchodilator FEV1 &gt; =80 % predict normal ( GLI 2012 ) postbronchodilator FEV1/FVC &gt; = low limit normal Mean DLCO acceptable measurement Visit 1 &gt; = 70 % predict normal value Further inclusion criterion apply Exclusion criterion : General Exclusion Criteria Previous participation study participation another trial investigational drug within 6 week prior Visit 1 study Respiratory tract infection COPD exacerbation 6 week prior Visit 1 screening period prior Visit 2 Significant pulmonary disease medical conditions* ( determined medical history , examination clinical investigation screen ) may opinion investigator result follow : 1 . Put subject risk participation study 2 . Cause concern regard subject 's ability participate study *e.g . rheumatoid arthritis , inflammatory bowel disease , severe liver disease , psoriasis , osteoporosis , hematological , infectious psychiatric disease Documented history asthma . For allergic rhinitis atopy , source documentation verify subject asthma Planned surgery study expect interfere study procedure outcome Blood withdrawal 100 mL within past 6 week prior Visit 1 Visit 1 2 Significant alcohol drug abuse within past 2 year prior Visit 1 Women pregnant , nursing plan become pregnant study Place permanent residence le 3 month prior Visit 1 For MRI subset : subject meet follow criterion Visit 2 : systolic blood pressure 90 180 mmHg ( SBP ) , diastolic blood pressure 50 110 mmHg ( DBP ) , pulse rate 40 110 bpm , ear temperature 35 37.5 C , glomerular filtration rate ( GFR ) &gt; = 30 mL/min A malignancy patient undergone resection , radiation chemotherapy within past 5 year . Patients treat basal cell carcinoma fully cure squamous cell carcinoma allow Inability comply restriction regard diet , life style medication Exclusion Criteria Specific Patients COPD A1AT Deficiency Newly add antiinflammatory treatment within 6 week prior Visit 1 Current treatment PDE ( Phosphodiesterase ) 5 inhibitor ( e.g . Roflumilast ) maintenance treatment Methylxanthines ( e.g . Theophylline ) Hospitalisation respiratory failure year prior Visit 1 A history cystic fibrosis Clinical diagnosis bronchiectasis require specific treatment Clinically relevant abnormal baseline hematology blood chemistry Known active tuberculosis Change therapy within 6 week prior Visit 1 Current plan A1AT augmentation therapy Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>